Wegovy, derived from semaglutide, acts as a GLP-1 receptor agonist, mimicking the GLP-1 hormone to reduce appetite by increasing insulin secretion and signaling feelings of fullness to the brain, he says
Practically speaking, dulaglutide is rarely chosen as a primary weight loss alternative to tirzepatide
VK2735: Phase 2 trial results for oral VK2735 are expected in the second half of 2025
Scenario 1: severe side effects on one medication If you tolerate semaglutide well for 3 to 4 months but then develop intolerable constipation or anxiety that does not respond to management strategies, switching to tirzepatide may provide relief
Having both licenses means Strive can serve individual patients and larger healthcare systems
Individual results vary based on dose, background medications, diet, and activity